Teva (TEVA) Shares Surge 85% With Focus on Branded Drugs

Teva Pharmaceutical Industries (NYSE: TEVA) shares have seen an 85% increase over the past 12 months as the company shifts from generic to branded drugs. The company expects earnings per share (EPS) to decline from $2.65 in 2025 to between $1.91 and $2.11 in 2026, partly due to the acquisition of Emalex Biosciences. Anticipated launches of biosimilars and other factors may result in a 30% increase in operating profit and adjusted EBITDA next year. A major upcoming drug, duvakitug, could significantly boost sales, with management estimating potential peak annual sales of $2 billion to $5 billion, making this stock appealing for investors.